BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines External R&D — BGB-43395 (CDK4 Inhibitor) by Year
External R&D — BGB-43395 (CDK4 Inhibitor) ($M) ($M)
BeOne Medicines External R&D — BGB-43395 (CDK4 Inhibitor): $18.0M in FY2025, up 195.7% from a year earlier.
Latest, FY2025
18.0
Period ended Dec 31, 2025
Change on a year earlier
+195.7%
6.08 in FY2024
History
3 years
Since FY2023
Sources
2
Documents cited below
Where the FY2025 figure comes from
“|| BGB-43395 (CDK4 Inhibitor) | 17,970 | 6,078”
Reported in Form 8-K EX-99.1 SSE STAR Market Annual Reports (688235.SS).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | External R&D — BGB-43395 (CDK4 Inhibitor) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 18.0 | +195.7% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2024 | Dec 31, 2024 | 6.08 | +250.5% | 8-K STAR Report (2026-04-14, 0001651308-26-000008) ↗ |
| FY2023 | Dec 31, 2023 | 1.73 | – | 8-K STAR Report (2025-04-28, 0001651308-25-000057) ↗ |
Cite this data
StockData. (2026). BeOne Medicines External R&D — BGB-43395 (CDK4 Inhibitor) ($M), annual FY2023–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-mol-bgb43395
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.